STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #524 by analyst upside · 2026-06-27
OCUL
Ocular Therapeutix, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+175.3%
implied upside to consensus target
Current Price $9.84
Consensus Target $27.09
Bull Target $34.0
Bear Target $18.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
7
Hold
0
Sell
0
52-Week Low $6.23
52-Week High $16.44
YTD Return -16.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -6.4x
EPS (TTM) $-1.44
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $52M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.23
52-Week High $16.44
Current Price $9.84
Bear Target $18.0
Bull Target $34.0
● Now $9.84 ● Target $27.09
TRADING DATA
Avg Volume 3.1M
YTD Return -16.8%
Analyst Count 11
Consensus Buy
Upside to Target +175.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Ocular Therapeutix, Inc. (OCUL) is currently trading at $9.84 with a Wall Street consensus price target of $27.09, implying potential upside of 175.3% over the next 12 months. 11 analysts currently cover OCUL, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $34.0, while the most cautious has a target of $18.0.

OCUL operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 16.8% year-to-date and is currently trading near the lower end of its 52-week range of $6.23 – $16.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OCUL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-18 31% win rate (48 calls)
Baird — Reiterated
Outperform → Outperform 2026-06-18 Building track record
RBC Capital reit
Outperform → Outperform 2026-05-06 Building track record
Needham reit
Buy → Buy 2026-05-05 20% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-13 31% win rate (48 calls)
Clear Street — Reiterated
Buy → Buy 2026-03-03 Building track record
Needham — Reiterated
Buy → Buy 2026-02-20 20% win rate (5 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-02-18 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →